SCHEMBL1049370

SCHEMBL1049370

O=c1[nH]ccc2c(-c3cccc(Cl)c3)cnc(Nc3ccccc3)c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ZAP70 P43403 2/20 0.46
NUDT1 P36639 1/20 0.46
TTBK1 Q5TCY1 2/20 0.45
TTBK2 Q6IQ55 1/20 0.45
IGF1R P08069 1/20 0.43
EIF4EBP1 Q13541 1/20 0.43
BRAF P15056 1/20 0.42
TNNI3K Q59H18 1/20 0.42
EGFR P00533 6/20 0.42
ABL1 P00519 3/20 0.42
CDK1 P06493 1/20 0.42
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
ADORA1 P30542 2/20 0.41
ADORA2A P29274 1/20 0.41
SRC P12931 1/20 0.40
PRKCA P17252 1/20 0.40
ABL2 P42684 1/20 0.40
PDE5A O76074 2/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1049635 0.89 ZAP70 (0.53) ZAP70TTBK1TTBK2IGF1REGFR
SCHEMBL1048512 0.88 ZAP70 (0.47) ZAP70TTBK1TTBK2EIF4EBP1BRAF
SCHEMBL1043299 0.88 JAK2 (0.49) ZAP70TTBK1TTBK2EIF4EBP1BRAF
SCHEMBL1045523 0.87 JAK2 (0.49) ZAP70TTBK1TTBK2IGF1RJAK2
SCHEMBL1043269 0.84 RIPK1 (0.46) ZAP70TTBK1IGF1REGFRJAK2
SCHEMBL1047107 0.84 LRRK2 (0.47) ZAP70ADORA1ADORA2AKDM4EALDH1A1
SCHEMBL1050006 0.84 BTK (0.56) ZAP70TTBK1TTBK2BRAFADORA1
SCHEMBL1049397 0.82 NUDT1 (0.48) ZAP70NUDT1TTBK1TTBK2IGF1R
SCHEMBL1048999 0.82 ZAP70 (0.49) ZAP70TTBK1TTBK2EGFRJAK2
SCHEMBL1048572 0.82 ZAP70 (0.45) ZAP70TTBK1TTBK2BRAFTNNI3K

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US claimed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US claimed
EP-2238137-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-10-13 EP claimed
WO-2009097287-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-08-06 WO claimed
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US disclosed
CN-101990539-A Compounds and compositions as kinase inhibitors IRM LLC 2011-03-23 CN disclosed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FYN, SYK, RET ZAP70 4/4885NUDT1 3348/4885TTBK1 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.